glp-1 and nad Premier Action OF GLP-1 agonists In
Description
Human Reproduction Open 2026
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks
Who May Benefit Most
Purpose of Review To discuss current literature and provide practical recommendations for the safe and effective use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in people with inflammatory bowel disease (IBD) and type 2 diabetes (T2D) and/or obesity
Get expert advice.
GLP-1 pills offer a needle-free approach to weight management
